ROQAF
Price
$0.02
Change
-$0.03 (-60.00%)
Updated
Jul 14 closing price
Capitalization
3.83M
Intraday BUY SELL Signals
SVRA
Price
$4.60
Change
+$0.43 (+10.31%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
935.95M
126 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ROQAF vs SVRA

Header iconROQAF vs SVRA Comparison
Open Charts ROQAF vs SVRABanner chart's image
Roquefort Therapeutics
Price$0.02
Change-$0.03 (-60.00%)
Volume$1K
Capitalization3.83M
Savara
Price$4.60
Change+$0.43 (+10.31%)
Volume$33.53K
Capitalization935.95M
ROQAF vs SVRA Comparison Chart in %
SVRA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ROQAF vs. SVRA commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ROQAF is a Hold and SVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ROQAF: $0.02 vs. SVRA: $4.60)
Brand notoriety: ROQAF and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ROQAF: 100% vs. SVRA: 236%
Market capitalization -- ROQAF: $3.83M vs. SVRA: $935.95M
ROQAF [@Biotechnology] is valued at $3.83M. SVRA’s [@Biotechnology] market capitalization is $935.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ROQAF’s FA Score shows that 1 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • ROQAF’s FA Score: 1 green, 4 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, SVRA is a better buy in the long-term than ROQAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SVRA’s TA Score shows that 4 TA indicator(s) are bullish.

  • SVRA’s TA Score: 4 bullish, 4 bearish.

Price Growth

ROQAF (@Biotechnology) experienced а 0.00% price change this week, while SVRA (@Biotechnology) price change was +11.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

SVRA is expected to report earnings on Mar 26, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SVRA($936M) has a higher market cap than ROQAF($3.83M). SVRA YTD gains are higher at: 49.837 vs. ROQAF (-57.300).
ROQAFSVRAROQAF / SVRA
Capitalization3.83M936M0%
EBITDAN/A-116.49M-
Gain YTD-57.30049.837-115%
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A146M-
Total DebtN/A29.7M-
FUNDAMENTALS RATINGS
SVRA: Fundamental Ratings
SVRA
OUTLOOK RATING
1..100
73
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
PROFIT vs RISK RATING
1..100
51
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SVRA
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
SVRA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
WIP38.79-0.08
-0.21%
SPDR® FTSE Intl Govt Infl-Protd Bd ETF
XTWY38.71-0.09
-0.24%
BondBloxx Bloomberg TwentyYrTrgDuUSTrETF
QQJG26.49-0.12
-0.45%
Invesco ESG NASDAQ Next Gen 100 ETF
ICF60.11-0.51
-0.83%
iShares Select U.S. REIT ETF
SPMC15.07-0.50
-3.21%
Sound Point Meridian Capital, Inc.

ROQAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ROQAF has been loosely correlated with GNTA. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ROQAF jumps, then GNTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROQAF
1D Price
Change %
ROQAF100%
N/A
GNTA - ROQAF
36%
Loosely correlated
-10.05%
CRBP - ROQAF
22%
Poorly correlated
-1.79%
SVRA - ROQAF
21%
Poorly correlated
+10.31%
SKYE - ROQAF
21%
Poorly correlated
N/A
SNTI - ROQAF
6%
Poorly correlated
+2.75%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with RCKT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
+10.31%
RCKT - SVRA
59%
Loosely correlated
-2.04%
PRTA - SVRA
46%
Loosely correlated
-3.57%
OCUL - SVRA
40%
Loosely correlated
+2.81%
AMLX - SVRA
38%
Loosely correlated
+2.80%
CRNX - SVRA
36%
Loosely correlated
-0.23%
More